GlycoFlux™ Human SIGLEC2 Overexpression Raji Cell Line (CAT#: GLJF-0925-JF1033)

Description	GlycoFlux™ human SIGLEC2 overexpression Raji cell line is a stable cell line engineered to overexpress SIGLEC2 (CD22), a B-cell lectin that binds sialic acid and regulates BCR signaling, endocytosis, and activation. It localizes to endosomes and is implicated in diffuse large B-cell lymphoma. This model supports research on B-cell biology, immune regulation, and lymphoma.
Product Type	Overexpression Cell Lines
Species	Human
Cell Morphology	Lymphoblast-like, suspension growth
Passage Ratio	1:2~1:4
Cell Line	Raji
Primary Disease	Burkitt's lymphoma
Lineage	B lymphocyte (B cell)
Lineage Subtype	Mature B cell, widely used in EBV-related studies

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	qPCR, Sanger Sequencing
Culture Medium	FBS & RPMI
Application	Mechanistic studies; Exploration of glycosylation and signaling pathways in cancer, metabolic, and immune-related diseases; Drug target validation and other functional assays.
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	SIGLEC2
Full Name	Sialic Acid Binding Ig Like Lectin 2
Alternative Name	SIGLEC-2; CD22; Sialic Acid Binding Ig Like Lectin
Location	19q13.12
Gene ID	8778
Summary	Predicted to enable CD4 receptor binding activity; protein phosphatase binding activity; and sialic acid binding activity. Involved in B cell activation; negative regulation of B cell receptor signaling pathway; and regulation of endocytosis. Located in early endosome and recycling endosome. Implicated in diffuse large B-cell lymphoma.